Immunovant, Inc. reported $25M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $25M (to Q4 2024). Net income: −$538M, trailing twelve months to Q1 2027. Free cash flow: −$407M, trailing twelve months to Q4 2026. EPS: −$2.82, trailing twelve months to Q1 2027.

IMVTImmunovant, Inc.

Healthcare

$30.48+106% 1Y

$30.48

$14.9052 weeks$45.00

IMVT as reported

Immunovant, Inc. reported $25M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$25M

Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied

Net income: −$538M
Net income · +20% year on year · trailing twelve months to Q1 2027
Free cash flow: −$407M
Free cash flow · trailing twelve months to Q4 2026
EPS: −$2.82
EPS · −0.70% year on year · trailing twelve months to Q1 2027

Details›

Every series Ryufin has for IMVT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$25M	n/a	Q4 2024 · 9 quarters behind
Net income	−$538M	+20%	Q1 2027
EPS	−$2.82	−0.70%	Q1 2027
Operating margin	−1229%	n/a	Q4 2024 · 9 quarters behind
Net margin	−1234%	n/a	Q4 2024 · 9 quarters behind
ROE	−67%	n/a	Q1 2027
ROA	−60%	n/a	Q1 2027
Free cash flow	−$407M	n/a	Q4 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.